Drug Profile
Research programme: adenosine receptor modulators - Neurocrine
Latest Information Update: 24 Feb 2011
Price :
$50
*
At a glance
- Originator Leiden University
- Developer Neurocrine Biosciences
- Class Small molecules
- Mechanism of Action Purinergic P1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 24 Feb 2011 No development reported - Preclinical for CNS disorders in Netherlands (unspecified route)
- 24 Feb 2011 No development reported - Preclinical for CNS disorders in USA (unspecified route)
- 02 Jul 2007 Preclinical development is ongoing